Prostate Cancer Liquid Biopsy Biomarkers' Clinical Utility in Diagnosis and Prognosis

被引:47
|
作者
Matuszczak, Milena [1 ]
Schalken, Jack A. [2 ]
Salagierski, Maciej [1 ]
机构
[1] Univ Zielona Gora, Coll Med, Dept Urol, PL-65046 Zielona Gora, Poland
[2] Radboud Univ Nijmegen, Med Ctr, Dept Urol, NL-6525 GA Nijmegen, Netherlands
关键词
cancer biomarkers; prostate cancer; liquid biopsy; prognosis; diagnosis; early detection; ANTIGEN; 3; PCA3; HEALTH INDEX; URINARY PCA3; SIGNIFICANTLY IMPROVES; 4-KALLIKREIN PANEL; EPIGENETIC ASSAY; ISOFORM P2PSA; MEN; RISK; PREDICT;
D O I
10.3390/cancers13133373
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary In prostate cancer, overdiagnosis and overtreatment is a common problem for clinicians. Accurate diagnosis and prognosis are essential to avoid unnecessary biopsy and to increases the effectiveness of treatment. A new, easy-to-use and non-invasive test based on liquid biopsy biomarkers such as Progensa PCA3, MyProstateScore, ExoDx, SelectMDx, PHI, 4K, Stockholm3 and ConfirmMDx have been developed to improve diagnosis, prognosis and to help guide the decision-making process. This article provides an overview of the above-mentioned commercial tests. The performance and financial aspects of the tests have been compared using available studies. Then the application of biomarker tests as an adjunct to multiparametric MRI in the diagnosis, prognosis and monitoring of prostate cancer has been discussed. Prostate cancer (PCa) is the most common cancer in men worldwide. The current gold standard for diagnosing PCa relies on a transrectal ultrasound-guided systematic core needle biopsy indicated after detection changes in a digital rectal examination (DRE) and elevated prostate-specific antigen (PSA) level in the blood serum. PSA is a marker produced by prostate cells, not just cancer cells. Therefore, an elevated PSA level may be associated with other symptoms such as benign prostatic hyperplasia or inflammation of the prostate gland. Due to this marker's low specificity, a common problem is overdiagnosis, which leads to unnecessary biopsies and overtreatment. This is associated with various treatment complications (such as bleeding or infection) and generates unnecessary costs. Therefore, there is no doubt that the improvement of the current procedure by applying effective, sensitive and specific markers is an urgent need. Several non-invasive, cost-effective, high-accuracy liquid biopsy diagnostic biomarkers such as Progensa PCA3, MyProstateScore ExoDx, SelectMDx, PHI, 4K, Stockholm3 and ConfirmMDx have been developed in recent years. This article compares current knowledge about them and their potential application in clinical practice.
引用
收藏
页数:29
相关论文
共 50 条
  • [1] Exosomal Liquid Biopsy in Prostate Cancer: A Systematic Review of Biomarkers for Diagnosis, Prognosis, and Treatment Response
    Hamid, Yameen
    Rabbani, Rukhshana Dina
    Afsara, Rakkan
    Nowrin, Samarea
    Ghose, Aruni
    Papadopoulos, Vasileios
    Sirlantzis, Konstantinos
    Ovsepian, Saak V.
    Boussios, Stergios
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2025, 26 (02)
  • [2] Metabolomic biomarkers in liquid biopsy: accurate cancer diagnosis and prognosis monitoring
    Wang, Wenqian
    Zhen, Shanshan
    Ping, Yu
    Wang, Liping
    Zhang, Yi
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [3] Clinical utility of emerging liquid biomarkers in advanced prostate cancer
    Vandekerkhove, Gillian
    Chi, Kim N.
    Wyatt, Alexander W.
    CANCER GENETICS, 2018, 228 : 151 - 158
  • [4] Clinical utility of emerging biomarkers in prostate cancer liquid biopsies
    Boerrigter, Emmy
    Groen, Levi N.
    Van Erp, Nielka P.
    Verhaegh, Gerald W.
    Schalken, Jack A.
    EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2020, 20 (02) : 219 - 230
  • [5] Markers of clinical utility in the differential diagnosis and prognosis of prostate cancer
    Kristiansen, Glen
    MODERN PATHOLOGY, 2018, 31 : S143 - S155
  • [6] Liquid Biopsy in Diagnosis and Prognosis of Non-Metastatic Prostate Cancer
    Rzhevskiy, Alexey S. S.
    Kapitannikova, Alina Y. Y.
    Butnaru, Denis V. V.
    Shpot, Evgeniy V. V.
    Joosse, Simon A. A.
    Zvyagin, Andrei V. V.
    Ebrahimi Warkiani, Majid
    BIOMEDICINES, 2022, 10 (12)
  • [7] Liquid Biopsy Potential Biomarkers in Prostate Cancer
    Neuhaus, Jochen
    Yang, Bo
    DIAGNOSTICS, 2018, 8 (04)
  • [8] Identification of biomarkers associated with pathological tumor staging and their utility in the diagnosis and prognosis of prostate cancer
    Xu, Shiquan
    Shi, He
    Liu, Yiran
    Lin, Jing
    Wu, Xia
    Lu, Ruichun
    Fan, Yu
    Tan, Weiqiang
    LABORATORY MEDICINE, 2024,
  • [9] Tumor-Derived Extracellular Vesicles as Liquid Biopsy for Diagnosis and Prognosis of Solid Tumors: Their Clinical Utility and Reliability as Tumor Biomarkers
    Dabral, Prerna
    Bhasin, Nobel
    Ranjan, Manish
    Makhlouf, Maysoon M.
    Abd Elmageed, Zakaria Y.
    CANCERS, 2024, 16 (13)
  • [10] Emerging Biomarkers for the Diagnosis and Prognosis of Prostate Cancer
    Sardana, Girish
    Dowell, Barry
    Diamandis, Eleftherios P.
    CLINICAL CHEMISTRY, 2008, 54 (12) : 1951 - 1960